Cannabinoid Neurobiology: Bridging Basic Science, Big Data, Biomarkers and Bedside Applications Across the Lifespan

The program is designed to highlight the latest advancements in cannabinoid neurobiology, focusing on how cannabinoids influence brain function across the lifespan. With an emphasis on bridging basic science, biomarkers, and big data, the conference will feature a diverse lineup of speakers and discussion leaders from around the globe. Sessions will delve into the effects of (endo/phyto)cannabinoids on multiple aspects of brain function, with impact on human health and disease guiding the discussion.

Endocannabinoids are critical regulators of neurotransmission in the brain, influencing adaptive and maladaptive responses through intricate signaling pathways. Despite significant progress in understanding their role in the CNS, many questions remain unanswered. As cannabis use becomes increasingly widespread due to changing legal and societal norms, it is essential to deepen our understanding of the neurobiological mechanisms influenced by the endocannabinoid system and the effects of cannabis constituents.

The 11th Gordon Research Conference on "Cannabinoid Neurobiology: Bridging Basic Science, Clinical Science, and Big Data Across the Lifespan" will bring together experts from diverse fields—including genetics, brain imaging, trauma, psychopharmacology, psychiatry, and big data science—to showcase their most recent discoveries. In-depth discussions will explore critical questions such as the genetics of cannabis use, the diversity of endocannabinoids, their cell type or regional specificity, the conditions under which they are mobilized, and the mechanisms by which aberrant endocannabinoid signaling may affect human health across the lifespan. The conference will also examine the use of big data and large imaging datasets to study brain development and comorbidities, as well as the therapeutic potential and risks associated with cannabinoids. Topics will include tools for studying cannabinoids in the human brain, leveraging biomarkers, and partnering with ongoing initiatives to broaden the impact of cannabinoid research.